114-80-7
Chemical Structure
Neostigmine Bromide
Synonym(s): Eustigmin bromide; Neoserine bromide
- CAS No.: 114-80-7
- Formula:C12H19BrN2O2
- Molecular Weight:303.20
IUPAC Name: 3-((dimethylcarbamoyl)oxy)-N,N,N-trimethylbenzenaminium bromide
InChIKey: LULNWZDBKTWDGK-UHFFFAOYSA-M
SMILES: C[N+](C)(C)C1=CC=CC(OC(N(C)C)=O)=C1.[Br-]
Biological Activity: Neostigmine (Eustigmin) Bromide is an orally active and reversible cholinesterase inhibitor that acts on myasthenia gravis to prolong and intensify the muscarinic and nicotinic effects of acetylcholine. Neostigmine Bromide can be used in anesthesia to reverse the neuromuscular blockade produced by competitive neuromuscular blockers[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Neostigmine Bromide | 99.91% | Neostigmine (Eustigmin) Bromide is an orally active and reversible cholinesterase inhibitor that acts on myasthenia gravis to prolong and intensify the muscarinic and nicotinic effects of acetylcholine. Neostigmine Bromide can be used in anesthesia to reverse the neuromuscular blockade produced by competitive neuromuscular blockers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Neostigmine Bromide (Standard) | ≥98% | Neostigmine (Bromide) (Standard) is the analytical standard of Neostigmine (Bromide). This product is intended for research and analytical applications. Neostigmine Bromide is a cholinesterase inhibitor that acts on myasthenia gravis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Nanjwade B K, et al. Development and evaluation of intranasal mucoadhesive microspheres of neostigmine bromide[J]. Pharm Anal Acta, 2011, 2(2): 1-6.
- [2]. Khorshid AF, et al. Modified carbon paste sensor for the potentiometric determination of neostigmine bromide in pharmaceutical formulations, human plasma and urine. Biosens Bioelectron. 2014 Jan 15;51:143-9. [Content Brief]
- [3]. SCHWAB RS, et al. Treatment of myasthenia gravis; prolonged action with multiple-dose tablets of neostigmine bromide and mestinon bromide. J Am Med Assoc. 1957 Oct 12;165(6):671-4. [Content Brief]
- [4]. Makkar R, et al. Development and validation of a stability-indicating method for neostigmine bromide: separation, identification and characterization of degradation product using LC-MS and ESI-Q-TOF-MS/MS[J]. Indian Journal of Pharmaceutical Sciences, 2022, 56: 1-13.
